Fmr LLC Reduces Stock Position in Cencora, Inc. (NYSE:COR)

FMR LLC lessened its position in Cencora, Inc. (NYSE:COR - Free Report) by 56.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,785,042 shares of the company's stock after selling 2,318,879 shares during the period. FMR LLC owned about 0.92% of Cencora worth $401,063,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in COR. JFS Wealth Advisors LLC raised its holdings in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Cencora in the fourth quarter worth about $30,000. Kentucky Trust Co purchased a new stake in shares of Cencora during the 4th quarter valued at about $33,000. Householder Group Estate & Retirement Specialist LLC raised its position in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares during the period. Finally, WASHINGTON TRUST Co grew its position in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares in the company, valued at approximately $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on COR. Bank of America boosted their price objective on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Evercore ISI increased their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $284.20.

Cencora Trading Down 0.0 %

COR stock traded down $0.12 during trading on Monday, hitting $284.21. The company had a trading volume of 1,215,027 shares, compared to its average volume of 1,508,174. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65. The company has a 50 day simple moving average of $260.27 and a 200-day simple moving average of $245.16. The firm has a market capitalization of $55.11 billion, a P/E ratio of 40.43, a PEG ratio of 1.31 and a beta of 0.55. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.